Bladder cancer: what's new in 2020-2021
https://doi.org/10.17650/1726-9776-2021-17-4-115-123
Abstract
This article aims to give an up-to-date review of studies on the diagnosis and treatment of patients with bladder cancer (BCa). We emphasize that the assessment of treatment and prognosis using specific markers is a promising method. However, clinical data currently outpace the results of molecular testing. Patients with luminal BCa demonstrate worse response to pharmacotherapy than those with other BCa types. The implementation of new drugs such as avelumab, enfortumab, and new drug combinations into clinical practice raised hopes to improve treatment outcomes of patients with locally advanced and metastatic bladder cancer. The development of new pharmacotherapy and immunotherapy regimens will improve treatment outcomes. We describe the experience of some foreign countries with the treatment and outpatient follow-up of patients after radical cystectomy. The article also contains the guidelines by the European Association of Urology on the treatment of patients with urinary tract cancers during the COVID-19 pandemic.
About the Author
O. B. Karyakin
A.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Oleg B. Karyakin.
4 Koroleva St., Obninsk 249031.
Competing Interests:
The author declares no conflict of interest.
References
1. EAU Guidelines. European Association of Urology, 2021.
2. Boormans J.L., De Jong J.J., Liu V.Y.T. et al. Luminal primary muscle-invasive bladder cancer patients are less likely to benefit from platinum-based neoadjuvant chemotherapy. Eur Urol 2021; 79(S 1):S1156.
3. Necchi A., DeJong J.J., Raggi D. Molecular characterization of residual bladder cancer after pembrolizumab. Eur Urol 2021;80(2):149-59. DOI: 10.1016/j.eururo.2021.03.014.
4. De Wit R., Kulkarni G.S., Uchio E. et al. Pembrolizumab for high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG): phase II KEYNOTE-057 Trial. ESMO 2018. Abstr. 3575.
5. De Wit R., Kulkarni G.S., Uchio E. et al. Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG). ESMO 2019. Abstr. 2829.
6. Balar A.V., Kamat A.M., Kulkarni G.S. et al. Pembrolizumab for the treatment of patients with high-risk (HR) nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin: extended follow-up of KEYNOTE-057 cohort A. ASCO GU 2021. Abstr. 451.
7. Flegar L., Baunacke M., Groeben C., Borkowetz A. Treatment trends for muscle-invasive bladder cancer in Germany from 2006 to 2018: Increasing case numbers facilitate more high-volume centers. Eur Urol 2021;79(S 1):S1148-50. DOI: 10.1016/S0302-2838(21)01201-X.
8. Bajorin D.F., Witjes J.A., Gschwend J., Schenker M. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). J Clin Oncol 2021;39(6_suppl):391. DOI: 10.1200/JCO.2021.39.6_suppl.391.
9. Van Hoogstraten L.M.C., Witjes J.A., Meijer R.P., Ripping T.M. Characteristics and survival of untreated versus treated patients with non-metastatic muscle invasive bladder cancer. Eur Urol 2021;79:S1166. DOI: 10.1016/S0302-2838(21)01210-0.
10. Khanna A., Zganjar A., Paras Shah P. et al. Is there value to routine oncologic surveillance after radical cystectomy? Comparative outcomes of symptomatic versus asymptomatic recurrence. J Clin Oncol 2021;39(6_suppl):421. DOI: 10.1200/JCO.2021.39.6_suppl.421.
11. Tural D., Olmez O.F., Sumbul A.T. et al. Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma. J Clin Oncol 2021;39(6_suppl):409. DOI: 10.1200/JCO.2021.39.6_suppl.409.
12. Powles Т., Rosenberg J.E., Sonpavde G. et al. Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma. J Clin Oncol 2021;39(6_suppl):393. DOI: 10.1200/JCO.2021.39.6_suppl.393.
13. Viswambaram P., Moe A., Chien Hern Liow E., Redfern A.D. Sub-urothelial durvalumab injection-1 (SUBDUE-1): a novel approach to immunotherapy for bladder cancer. J Clin Oncol 2021; 39(6_suppl):TPS503. DOI: /10.1200/JCO.2021.39.6_suppl. TPS503.
14. Powles T., Meeks J.J., Galsky M.D., van der Heijden M. A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA). J Clin Oncol 2021;39(6_suppl):TPS505. DOI: 10.1200/JCO.2021.39.6_suppl.TPS505.
15. Catto J.W.F., Downing А., Mason S. et al. Quality of life after bladder cancer: a cross-sectional survey of patient-reported outcomes. Eur Urol 2021;79(5):621-32. DOI: 10.1016/j.eururo.2021.01.032.
16. Wallis C.J.D., Catto J.W.F., Finelli A. et al. The Impact of the COVID-19 pandemic on genitourinary cancer care: re-envisioning the future. Eur Urol 2020;78(5):731-42. DOI: 10.1016/j.eururo.2020.08.030.
Review
For citations:
Karyakin O.B. Bladder cancer: what's new in 2020-2021. Cancer Urology. 2021;17(4):115-123. (In Russ.) https://doi.org/10.17650/1726-9776-2021-17-4-115-123
Views:
565
Email this article 